Results 201 to 210 of about 313,710 (255)
Some of the next articles are maybe not open access.
Current Cancer Drug Targets, 2010
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara +5 more
openaire +3 more sources
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara +5 more
openaire +3 more sources
Current Opinion in Oncology, 1997
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire +2 more sources
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire +2 more sources
FLT3 Tyrosine Kinase Inhibitors
International Journal of Hematology, 2005The receptor tyrosine kinase FLT3 is an important regulatory molecule in hematopoiesis and is expressed on the blasts in most cases of acute leukemia. Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are associated with a distinctly worse clinical outcome.
Mark, Levis, Donald, Small
openaire +2 more sources
Tyrosine kinase inhibitors and the thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 2009Protein tyrosine kinase inhibitors (TKIs) have emerged as significant targets for novel cancer therapies. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, multiple novel therapies primarily targeting angiogenesis have entered clinical trials.
openaire +2 more sources
Inhibitors of protein tyrosine kinases
Current Opinion in Biotechnology, 1995The description in the past year of several novel protein tyrosine kinase inhibitors, which exhibit dramatic improvements in potency and specificity over earlier agents, will be considered a major turning point in the field. These compounds appear to have the necessary pharmacological properties to finally allow clarification of whether suppression of ...
D W, Fry, A J, Bridges
openaire +2 more sources
Neoadjuvant Tyrosine Kinase Inhibitors
Thoracic Surgery ClinicsNeoadjuvant tyrosine kinase inhibitor (TKI) therapy has appeal given the potential for early systemic disease control and tumor downstaging prior to surgery. Until recently, data has have come from smaller series with outcomes from larger trials, including NeoADAURA, ALNEO, and NAUTIKA1, reporting early results. Neoadjuvant use of TKI has been shown to
Gavitt A, Woodard +2 more
openaire +2 more sources
Metal-Tyrosine Kinase Inhibitors: Targeted metal-drug conjugates
Coordination Chemistry Reviews, 2022Trinidad Velasco-Torrijos +2 more
exaly
Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors
Pharmacology & Therapeutics, 1999Pascal Furet, Peter Traxler, P Traxler
exaly
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Therapeutic Advances in Medical Oncology, 2020Laurence Albiges +2 more
exaly